LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

TG Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

32.53 1.85

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

31.77

Max

32.54

Galvenie mērījumi

By Trading Economics

Ienākumi

23M

28M

Pārdošana

20M

141M

P/E

Sektora vidējais

85.811

35.293

Peļņas marža

19.97

Darbinieki

370

EBITDA

25M

38M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+19.57% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 3. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

543M

5.1B

Iepriekšējā atvēršanas cena

30.68

Iepriekšējā slēgšanas cena

32.53

Ziņu noskaņojums

By Acuity

44%

56%

156 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

TG Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 18. sept. 23:56 UTC

Karstas akcijas

Stocks to Watch: FedEx, 22nd Century, Scholastic

2025. g. 18. sept. 22:01 UTC

Galvenie tirgus virzītāji

22nd Century Group Shares Gain on Debt Repayment, New Capital

2025. g. 18. sept. 20:51 UTC

Iegādes, apvienošanās, pārņemšana

UPS Terminates Plan to Buy Estafeta

2025. g. 18. sept. 20:31 UTC

Peļņas

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

2025. g. 18. sept. 20:26 UTC

Peļņas

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

2025. g. 18. sept. 23:43 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 18. sept. 23:43 UTC

Tirgus saruna

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

2025. g. 18. sept. 23:43 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 18. sept. 23:40 UTC

Tirgus saruna

Gold Edges Lower Amid Cautious Mood -- Market Talk

2025. g. 18. sept. 23:31 UTC

Tirgus saruna

FedEx Says U.S. Demand Is Resilient -- Market Talk

2025. g. 18. sept. 22:03 UTC

Peļņas

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

2025. g. 18. sept. 22:01 UTC

Peļņas

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

2025. g. 18. sept. 21:56 UTC

Peļņas

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

2025. g. 18. sept. 21:54 UTC

Peļņas

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

2025. g. 18. sept. 21:48 UTC

Peļņas

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

2025. g. 18. sept. 21:47 UTC

Peļņas

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

2025. g. 18. sept. 21:17 UTC

Peļņas

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

2025. g. 18. sept. 21:07 UTC

Peļņas

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

2025. g. 18. sept. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 18. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 18. sept. 20:50 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2025. g. 18. sept. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2025. g. 18. sept. 20:22 UTC

Iegādes, apvienošanās, pārņemšana

UPS Cites Inability of All Closing Conditions to Be Satisfied

2025. g. 18. sept. 20:22 UTC

Iegādes, apvienošanās, pārņemšana

United Parcel Service Terminates Plan to Buy Estafeta

2025. g. 18. sept. 20:20 UTC

Iegādes, apvienošanās, pārņemšana

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

2025. g. 18. sept. 20:18 UTC

Peļņas

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

2025. g. 18. sept. 20:18 UTC

Peļņas

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

2025. g. 18. sept. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 18. sept. 20:07 UTC

Peļņas

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

2025. g. 18. sept. 20:03 UTC

Peļņas

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Salīdzinājums

Cenas izmaiņa

TG Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

19.57% augšup

Prognoze 12 mēnešiem

Vidējais 38.25 USD  19.57%

Augstākais 55 USD

Zemākais 11 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi TG Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

4 ratings

2

Pirkt

1

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 34.86Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

156 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat